Innovating Works

PRECISESADS

Financiado
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Aut...
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases We concur to the IMI on Reclassification of SLE, connective tissue diseases and RA call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share com... We concur to the IMI on Reclassification of SLE, connective tissue diseases and RA call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therapeutic agents that are being developed for one disease but cannot be applied in another due to current clinical classifications. We will investigate individuals with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren’s syndrome (Sjs), rheumatoid arthritis (RA), primary antiphospholipid syndrome (PAPS) and mixed connective tissue disease (MCTD), jointly as systemic autoimmune diseases (SADs). We believe that there will be overlapping clusters of individuals across diseases that will share molecular features. To determine these clusters we will, study 2000 cases of SADs, and 600 healthy controls to identify molecular clusters and their cellular and clinical correlates. In addition, we will study kidney and skin biopsies to define the development of molecular markers with severe kidney disease or with skin fibrosis. In this way we will define systemic and tissue taxonomies. We will study complete as well as isolated peripheral blood mononuclear cells and subpopulations and in biopsies gene expression and epigenetic marks with a combination of array and next generation sequencing (NGS) strategies. These studies will define cellular counts and proportions and changes in gene expression related to specific cellular populations. We will also use NGS strategies to define the presence of risk alleles (HLA and non-HLA) in all individuals. The data will be complemented with the study of the presence of autoantibodies in serum (analyzed in a reference lab), and we will use metabolomics mass spectrometry and NMR approaches to analyze plasma and urine metabolites. We will also study exosomes in plasma and urine and identify their molecular profiles. Samples will be collected following strict protocols and appropriate patient selection. The bioinformatics and biostatistics approaches will be aimed at the analysis of clusters with unsupervised clustering algorithms and tools and cross-validation. We will also perform analyses to determine risk and predictive models analyzing the genetic and molecular data at different levels, leading to a highly productive study with two arms, one for basic research and one with clinical applications. Among the clinical applications we will have a new classification for groups of patients sharing molecular mechanisms of disease, biomarkers for disease progression and organ damage prediction, and we will develop assays that can be easily applied in the clinic. The resultant clinically applicable clusters will be then validated in a longitudinal, inception trial where newly recruited patients will be analyzed at baseline and at two different time points and define their clustering status or their evolution towards specific clusters. We will gain completely novel information that will open new avenues of research and new possibilities of collaboration between the public Academy and the private Pharmaceutical sector by establishing the basis for new clinical trials with the potential to really benefit the patients. ver más
31/01/2019
UCB
23M€

Línea de financiación: concedida

El organismo FP7 notifico la concesión del proyecto el día 2019-01-31
Presupuesto El presupuesto total del proyecto asciende a 23M€
Líder del proyecto
UCB BIOPHARMA No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5